LAVA Therapeutics NV Cash Flow-to-Debt Ratio
LAVA Therapeutics NV cash flow-to-debt ratio. LAVA Therapeutics NV (LVTX) has a Cash Flow-to-Debt Ratio of -0.12x as of September 2025, meaning its operating cash flow of $-4.87 Million could theoretically repay 0% of its total liabilities ($39.23 Million) in one year. Check LVTX cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of LAVA Therapeutics NV (2019–2024)
Cash flow-to-debt ratio of LAVA Therapeutics NV from 2019 to 2024. Historical debt coverage capacity for LAVA Therapeutics NV across 6 annual periods. Check LVTX capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
LAVA Therapeutics NV Cash Flow-to-Debt Ratio by Year (2019–2024)
LAVA Therapeutics NV cash flow-to-debt ratio by year from 2019 to 2024. Year-by-year debt coverage analysis for LAVA Therapeutics NV. For the full cash flow conversion analysis, see cash efficiency ratio of LAVA Therapeutics NV.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.37x | $-19.54 Million | $53.09 Million | ▲ +53.8% |
| 2023 | -0.80x | $-40.28 Million | $50.53 Million | ▼ -1231.5% |
| 2022 | 0.07x | $4.04 Million | $57.38 Million | ▲ +105.1% |
| 2021 | -1.37x | $-28.65 Million | $20.88 Million | ▼ -89.6% |
| 2020 | -0.72x | $-9.31 Million | $12.87 Million | ▲ +75.2% |
| 2019 | -2.92x | $-8.62 Million | $2.95 Million | — |